- Home
- SLP vs RNA Comparison
SLP vs RNA Comparison
Compare SLP & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLP | RNA |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.6M | 217.5M |
| IPO Year | 1996 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SLP | RNA |
|---|---|---|
| Price | $14.80 | $13.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 20 |
| Target Price | $24.00 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 371.2K | 337.2K |
| Earning Date | 04-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $59,577,000.00 | N/A |
| Revenue This Year | $3.80 | $88.12 |
| Revenue Next Year | $5.90 | $18.11 |
| P/E Ratio | $54.23 | ★ N/A |
| Revenue Growth | ★ 10.52 | N/A |
| 52 Week Low | $11.09 | $11.95 |
| 52 Week High | $34.01 | $73.06 |
Technical Indicators
Market Signals| Indicator | SLP | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 34.20 |
| Support Level | $14.18 | $12.85 |
| Resistance Level | $15.37 | $14.80 |
| Average True Range (ATR) | 0.72 | 0.66 |
| MACD | -0.01 | 0.71 |
| Stochastic Oscillator | 67.16 | 39.23 |
Price Performance
Historical ComparisonAbout SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.